Advertisement
Novinky na Forexu
Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL
Novartis AG (NVS) announced Monday it has recalled one lot of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles. The company added that no other Sandimmune formulations are impacted.
RTTNews |
Před 709 dny
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews
|
Před 709 dny
JetBlue, Allegiant Ink Divestiture Deal In Connection With JetBlue's Combination With Spirit
JetBlue Airways Corp. (JBLU) and Allegiant (ALGT) announced Monday that the airlines have entered into a definitive agreement under which JetBlue will transfer to Allegiant all of the holdings of Spirit Airlines, Inc. (SAVE) at Boston Logan International Airport and Newark Liberty International Airport.
RTTNews
|
Před 709 dny
U.S. Dollar Lower Ahead Of Inflation Data
The U.S. dollar fell against its most major rivals in the European session on Monday, as investors await U.S. inflation data that could influence the Federal Reserve's interest rate path for the rest of the year.
RTTNews
|
Před 709 dny
Neumora Therapeutics Announces IPO Of 14.71 Mln Shares To Be Priced Between $16.00 And $18.00/Share
Biopharmaceutical company Neumora Therapeutics, Inc. revealed Monday that it will offer 14.71 million shares of its common stock in an initial public offering and expects the IPO price to be between $16.00 and $18.00 per share, according to an amended Form S-1 filing with the U.S. Securities and Exchange Commission.
RTTNews
|
Před 709 dny
RayzeBio Announces IPO Of 14.40 Mln Shares To Be Priced Between $16.00 And $18.00/Share
Radiopharmaceutical therapeutics company RayzeBio, Inc. revealed Monday that it will offer 14.40 million shares of its common stock in an initial public offering and expects the IPO price to be between $16.00 and $18.00 per share, according to an amended Form S-1 filing with the U.S. Securities and Exchange Commission.
RTTNews
|
Před 709 dny
Eurozone To Undergo Slower Growth On Subdued Domestic Demand, Tight Policy
The euro area economy is set to log a weaker-than-estimated growth this year and next as rising consumer prices continue to weigh on domestic demand and monetary policy tightening works its way through the economy. In the summer interim forecast, released Monday, the European Commission said the 20-nation currency bloc will grow 0.8 percent in 2023, which was revised down from 1.1 percent projec
RTTNews
|
Před 709 dny
more news
Bird Global Appoints Joseph Prodan To Succeed Michael Washinushi As CFO
Electric transportation company Bird Global, Inc. (BRDS) announced Monday the appointment of Joseph (Joe) Prodan as Chief Financial Officer (CFO), effective August 30, 2023. Prodan succeeds Michael Washinushi, following his recent appointment to Interim CEO.
RTTNews
|
Před 709 dny
Kellogg Board Approves Separation Into Two Independent, Publicly Traded Companies
Kellogg Co. (K) announced Monday that its Board of Directors formally approved the previously announced separation into two independent, publicly traded companies, Kellanova and WK Kellogg Co.
RTTNews
|
Před 709 dny
InflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904
Biotechnology company InflaRx N.V. (IFRX) announced Monday topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904.
RTTNews
|
Před 709 dny
Bay Street Likely To Open Higher
Canadian shares are likely to open on a positive note on Monday, tracking European markets and higher bullion prices.
RTTNews
|
Před 709 dny
Welltower Boosts FY23 NFFO Guidance
Healthcare infrastructure company Welltower Inc. (WELL) on Monday raised its earnings guidance for the full-year 2023.
RTTNews
|
Před 709 dny
Moderna, Immatics Ink Strategic Multi-Platform Collaboration To Develop Oncology Therapeutics
Biopharmaceutical company Moderna, Inc. (MRNA) and Germany-based Immatics N.V. (IMTX) announced Monday a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
RTTNews
|
Před 709 dny
Stay up to date!
Add Zprávy to your browser
Add To Chrome
